Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rise of Generics and Patent Expirations Sees CPhI and P-MEC India 2013 Expand

Published: Tuesday, December 03, 2013
Last Updated: Monday, December 02, 2013
Bookmark and Share
Free online registration to attend CPhI and P-MEC India is now closed.

CPhI has announced that CPhI and P-MEC India, ran by leading events organizer UBM, is returning to the Bombay Convention and Exhibition Centre, Mumbai (India) from the 3rd to the 5th December 2013.

The event will return with an increased scale, continuing its commitment to cater to all sectors of the pharma industry by co-locating with ICSE and BioPh India.

With a view to enhancing the customer experience and ROI value, CPhI India has enhanced the mobile application, now available on all mobile devices with an internet connection, designed to help attendees navigate their way around the event, drive traffic to stands and stay up to date with schedules and speaker events.

With the addition of hall 7, P-MEC will host even more exhibitors than previous years. Last year, there were 926 exhibitors present and this is expected to rise to 1,000 this year to create the biggest show to date.

Free online registration to attend CPhI and P-MEC India is now closed, however registration is still possible in Mumbai, the onsite fee is only INR500.

India has increasingly become a focal point of the pharmaceutical industry and is now the third largest in terms of volume. The country is fast becoming an innovation hub, increasingly matching Western standards, whilst also reducing the costs of manufacturing, showcasing the Indian pharma markets unique position and providing an optimum investment platform for international companies.

Outside of the US, India has the highest number of FDA approved facilities (546), and the Indian pharma sector received USFDA approvals for around 40% of all Abbreviated New Drug Approvals (ANDA) during January-July 2013.

Further, with R&D investments rapidly advancing, coupled with the rise in generics and supergenerics, India represents a key maturing market, with CPhI and P-MEC India facilitating opportunities to drive and enhance the sector.

Ahead of the event, the UBM India pharma awards will take place on 2nd December, celebrating the most innovative and dynamic areas across the Indian pharma community.

Honouring companies who are driving forward industry changing initiatives, there will be awards for multiple categories including ‘Excellence in Product Development’, ‘Excellence in Contract Research’ and ‘Excellence in Packaging Development’.

The evening will also host a panel discussion on ‘Moving up the Global Pharma Value Chain’, designed to inform and educate those present at the awards ceremony.

“The global pharmaceutical market has seen a significant shift over the last year, particularly as patent expirations are becoming more frequent and a potential patent cliff is shaking the industry. India, however, is thriving as the demand for generics is on the rise and companies are looking to drive down manufacturing costs. India is well positioned to accommodate increased demand, providing expertise in development and manufacturing. CPhI and P-MEC India will provide the ideal and essential platform for international and domestic suppliers and buyers to break into the market,” Chris Kilbee, Group Director, Pharma.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CPhI China Report Predicts Domestic Growth to Outpace Exports
Emerging cities, biopharmaceuticals and APIs to drive future expansion.
Friday, August 14, 2015
CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand
International companies looking to gain a foothold in this lucrative and gentrifying pharma economy.
Tuesday, August 11, 2015
CPhI Korea Opens as South Korea Emerges as Global Leader in Biosimilar Trials
Government’s R&D strategy and “Pharma 2020 Vision” to see country as drug development leader.
Monday, July 27, 2015
CPhI Announces USA Market Report at InformEx
Country report to contain contrasting insights into the American pharma economy from European and domestic perspectives.
Wednesday, January 22, 2014
Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
Kilbee responsible for driving the portfolio globally including increased emphasis on digital and content.
Monday, January 13, 2014
CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
Growth in the World’s second largest pharma region facilitated by innovation and loosened regulatory guidelines.
Monday, December 30, 2013
John van der Valk Appointed MD of UBM Live Amsterdam
Valk responsible for overseeing the company’s flagship brand CPhI.
Monday, December 23, 2013
CPhI Worldwide 2013 Hosted More Than 34,000 Global Pharma Professionals
This year sees strong growth in APIs, biopharma, natural extracts, packaging and finished dosage with a highlight on innovation.
Tuesday, November 26, 2013
India Sets Ambitious Pharma Export Growth Targets
Indian generics exports growing at 24% per annum.
Monday, October 21, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!